KFSHRC Detects 276 Fetal Genetic Disorders Through Prenatal Care Saving SAR 360 Million Annually - Middle East Business News and Information
King Faisal Specialist Hospital & Research Centre (KFSHRC) is enhancing prenatal care through innovation and precision medicine. By testing more than 300 genes, KFSHRC has provided early insights to 1,104 pregnant women, preventing 276 genetic disorders and saving the Saudi healthcare system 360 million riyals.
KFSHRC's Preventive Fetal Screening Program identifies genetic risks and ensures targeted care during critical pregnancy stages. Paired with technologies like Next-Generation Sequencing (NGS) and Non-Invasive Prenatal Testing (NIPT), these advancements enhance the precision and safety of prenatal diagnostics, benefiting 1,500 families annually. The Program has expanded its capacity to detect more than 500 additional genetic diseases, equipping families with early insights, reducing the birth of new-borns with severe genetic diseases, and improving overall offspring outcomes and well-being.
From screenings to therapeutic procedures and advanced surgical interventions, KFSHRC ensures well-being and trust remain at its core, shaping a healthier future for families. These efforts were recognised in 2023 when the prenatal department won a Performance Improvement Award for improving the patient experience through care accessibility and innovation.
It is noteworthy that KFSHRC has been ranked first in the Middle East and North Africa and 15 th globally in the list of the world's top 250 Academic Medical Centres for the second consecutive year and has been recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
3 days ago
- Mid East Info
KFSHRC Pioneering Clinical Trials and Gene Therapy Across the Region - Middle East Business News and Information
As part of Saudi Arabia's broader biotechnology transformation under Vision 2030, King Faisal Specialist Hospital & Research Centre (KFSHRC) solidified its role as the Kingdom's leading Clinical Trials hub in 2024 — conducting 52.4% of all active Clinical Trials nationwide, according to the Saudi National Institute of Health. This milestone reflects the sustained success of KFSHRC's Clinical Trials Transformation Initiative, launched in 2021 to build an integrated, patient-centered research ecosystem. By the end of 2024, the hospital had recorded 701 active research proposals, representing an 8% increase over the previous year. In Riyadh alone, research approvals rose by 20%, demonstrating growing alignment between scientific discovery and clinical care delivery. KFSHRC's research growth was matched by key innovation milestones. In 2024, it became the first in Saudi Arabia to locally produce CAR-T cells — a major step toward national self-sufficiency in advanced therapies. It also delivered a breakthrough in hemophilia care, using one-time gene therapy to restore clotting function in eight patients, eliminating preventive treatment and significantly improving quality of life. These advancements align closely with Saudi Arabia's Vision 2030 and National Biotechnology Strategy, which designate biotechnology as a national priority sector — aiming to localize therapeutic development, accelerate innovation, and establish global leadership by 2040. Complementing its scientific leadership, KFSHRC has also invested in public engagement, launching awareness campaigns in high-traffic public venues to promote Clinical Trials literacy and reduce misconceptions around participation. It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally among the world's top 250 Academic Medical Centres for the third consecutive year, and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
Mid East Info
3 days ago
- Mid East Info
On-Road Mobile Stations Support Hajj Pilgrims During Bus Breakdowns - Middle East Business News and Information
Mecca Saudi Arabia's Roads General Authority has introduced mobile service pods along the Hijrah Expressway that connects Makkah and Madinah. These stations are intended to assist pilgrims whose buses experience mechanical issues en route. For many pilgrims, the journey between Mecca and Madinah is spiritual and physically demanding. Unexpected bus breakdowns can add to the challenges, leaving pilgrims stranded under the scorching sun. Inaugurated by Saudi Minister of Transport and Logistics Services Saleh Al-Jasser, these mobile units are strategically located along the Hijrah Expressway to support distressed pilgrims. In addition to providing physical assistance, they create a feeling of safety and compassion, reflecting the Kingdom's commitment to the well-being of each pilgrim. Each mobile unit can host 40 pilgrims and features air conditioning, seating, restrooms, and facilities for serving cold drinks and meals. Functioning 24/7 during the Hajj season, these stations are designed to offer prompt relief and comfort to pilgrims in need. This initiative is part of a larger effort by Saudi authorities to guarantee the safety and well-being of all pilgrims.
Daily News Egypt
5 days ago
- Daily News Egypt
Egypt becomes first country in Eastern Mediterranean to meet WHO target for hepatitis B control
Egypt has become the first country in the World Health Organization's Eastern Mediterranean Region to meet the WHO target for hepatitis B control, a milestone achievement officially recognized during a ceremony held in Cairo on Sunday. At the event, Deputy Prime Minister and Minister of Health Khaled Abdel Ghaffar received a formal certificate from WHO, confirming Egypt's success in achieving the benchmark for reducing hepatitis B prevalence among children and maintaining sustained vaccine coverage. According to national surveys conducted between 2008 and 2024, hepatitis B prevalence among individuals under 60 has declined by 15% since 2015, while rates among children under ten have dropped by 50%. Notably, prevalence among children under five now stands at below 1%—the threshold established by WHO for hepatitis B control. WHO Regional Director for the Eastern Mediterranean, Hanan Balkhy, praised Egypt's public health infrastructure and long-standing commitment to immunization. She highlighted that Egypt has maintained over 90% coverage of the hepatitis B third-dose vaccine for more than a decade, as well as consistent coverage of the birth dose for five consecutive years. 'This is a turning point in Egypt's healthcare journey,' said Abdel Ghaffar. 'It reflects our national commitment to prevention, immunization, and universal health coverage, in alignment with President Abdel Fattah Al-Sisi's vision for health security.' The success was largely driven by Egypt's Expanded Program on Immunization (EPI), which achieved over 95% vaccine coverage, providing free hepatitis B vaccines to all newborns—Egyptian and non-Egyptian alike. The program also ensures immediate birth doses and immunoglobulin for infants born to hepatitis B-positive mothers. Egypt also expanded immunization access to high-risk populations, including healthcare workers, dialysis patients, people living with HIV, and household contacts of hepatitis B carriers. These efforts were supported by upgrades to the digital infrastructure that improved vaccine tracking, reduced waste, and ensured equitable service delivery across the country. WHO Representative in Egypt, Naeema Al-Gasseer, commended Egypt for its technical capacity and long-term planning. 'Egypt fully deserves this recognition. It is a testament to what can be achieved through coordinated health policy and sustained investment in public health.' Beyond immunization, the Ministry of Health launched the Egyptian Vaccine Manufacturers Alliance (EVMA) to localize vaccine production and strengthen domestic supply chain resilience, a key pillar in Egypt's drive toward health system sustainability. Hesham Sateet, Head of the Unified Procurement Authority, emphasized the importance of securing vaccines and medical supplies through transparent, efficient mechanisms. 'This achievement would not have been possible without the full backing of Egypt's political leadership and the close coordination among state institutions,' he said. Ali El-Ghamrawy, President of the Egyptian Drug Authority, added that local manufacturing and regulatory governance are central to Egypt's broader health strategy, which is aligned with Vision 2030 and the UN Sustainable Development Goals. 'The Egyptian experience proves that with strategic planning, institutional coordination, and political will, even complex public health challenges can be overcome,' Abdel Ghaffar concluded, expressing gratitude to frontline health workers and international partners who supported Egypt's journey.
